Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS by Lee, Kathy et al.
Lee et al. BMC Neurology 2010, 10:44
http://www.biomedcentral.com/1471-2377/10/44
Open Access RESEARCH ARTICLE
© 2010 Lee et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons At-
tribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Research article Clinical outcomes and immune benefits of 
anti-epileptic drug therapy in HIV/AIDS
KathyLee†1, Pornpun Vivithanaporn†2,3, Reed A Siemieniuk1, Hartmut B Krentz1,4, Ferdinand Maingat2, M John Gill1,4,5 
and Christopher Power*1,2,5
Abstract
Background: Anti-epileptic drugs (AEDs) are frequently prescribed to persons with HIV/AIDS receiving combination 
antiretroviral therapy (cART) although the extent of AED use and their interactions with cART are uncertain. Herein, 
AED usage, associated toxicities and immune consequences were investigated.
Methods: HIV replication was analysed in proliferating human T cells during AED exposure. Patients receiving AEDs in a 
geographically-based HIV care program were assessed using clinical and laboratory variables in addition to assessing 
AED indication, type, and cumulative exposures.
Results: Valproate suppressed proliferation in vitro of both HIV-infected and uninfected T cells (p <0.05) but AED 
exposures did not affect HIV production in vitro. Among 1345 HIV/AIDS persons in active care between 2001 and 2007, 
169 individuals were exposed to AEDs for the following indications: peripheral neuropathy/neuropathic pain (60%), 
seizure/epilepsy (24%), mood disorder (13%) and movement disorder (2%). The most frequently prescribed AEDs were 
calcium channel blockers (gabapentin/pregabalin), followed by sodium channel blockers (phenytoin, carbamazepine, 
lamotrigine) and valproate. In a nested cohort of 55 AED-treated patients receiving cART and aviremic, chronic 
exposure to sodium and calcium channel blocking AEDs was associated with increased CD4+ T cell levels (p <0.05) 
with no change in CD8+ T cell levels over 12 months from the beginning of AED therapy.
Conclusions: AEDs were prescribed for multiple indications without major adverse effects in this population but 
immune status in patients receiving sodium or calcium channel blocking drugs was improved.
Background
Anti-epileptic drugs (AEDs) are frequently used as
adjunct therapies for several conditions aside from epi-
lepsy and seizures including movement disorders, mood
disorders and neuropathic pain [1,2]. The individual
choice of AED is usually made based on the specific indi-
cation and potential drug side-effect profile such as
hepatic or renal dysfunction, leukopenia, and the
patient's co-morbidities as well as concurrent treatments.
Nevertheless, monitoring blood AED levels can reduce
the incidence of specific AED side-effects. Co-morbid
diseases often complicate the use of AEDs, in large part
because of their consequences such as organ failure and/
or neuropsychiatric effects [3,4]. Human immunodefi-
ciency virus (HIV) infection is associated with a higher
prevalence of neuropathic pain (25-50%) [5], seizures/
epilepsy (3-6%) [6,7], and mood disorders [8] than within
the general population and often require AED treat-
ment(s) [9-11]. However, the prescription of AEDs in the
context of HIV infection, especially in the acquired
immunodeficiency disease syndrome (AIDS) phase, can
present substantial clinical challenges, given the accom-
panying risks of hepatic or renal failure together with the
increasingly complex range of antiretroviral therapies
prescribed for HIV/AIDS. Indeed, some components of
combination antiretroviral therapy (cART) such as pro-
tease inhibitors often pose serious risks in terms of drug
interactions, occasionally with life threatening conse-
quences in individuals who already have multi-organ dis-
eases [12,13]. Despite these concerns, AEDs continue to
be used widely in HIV/AIDS patients receiving cART,
albeit with uncertainty regarding potential adverse conse-
quences. The full spectrum of AED use in HIV-infected
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patients remains unknown, nor is the risk of adverse
effects accompanying AED use. Moreover, clinicians car-
ing for patients who receive both AEDs and concurrent
antiretroviral drugs face clinical dilemmas arising from
the potential interactions between both classes of drugs.
Little is known about the impact AEDs on immunologic
and virologic markers during HIV infection although in
vitro studies suggest that some AEDs (valproate) might
enhance viral replication while the in vivo effects remain
less certain [14].
Given these complex circumstances, the working
h ypo t h e s i s  w a s:  a s  A E D s  a r e  f r eq u e n t l y  p r e s c r i bed  f o r
protracted periods for a variety of conditions in HIV/
AIDS patients, AEDs might exert substantial effects on
virologic, immunologic and clinical outcomes. Viremic
status provides a robust indicator of control of HIV infec-
tion, which can be used to monitor potentially adverse
effects of other interventions such as AEDs initiation, as
assessed in the present studies. Herein, we investigated
the extent and impact of AED use among aviremic and
viremic persons with HIV/AIDS attending a regional HIV
program as well as the in vitro effects of frequently used
AEDs on T cell proliferation and HIV replication.
Methods
Laboratory studies
Primary human peripheral blood lymphocytes (PBLs)
were purified from healthy HIV seronegative subjects'
blood with Histopaque (Sigma) and maintained in RPMI
1640 medium with 15% FBS with phytohemagglutinin-P
(PHA-P) stimulation for 3 days, followed by hIL-2 stimu-
lation and/or an anti-hCD3 monoclonal antibody (eBio-
science, San Diego, CA) for the duration of the
experiment [15]. HIV-1 SF162 stocks were used to infect
PBLs at day 3 post-isolation of the cells and then treated
with gabapentin, valproate or phenytoin (20, 75 and 15
μg/ml, respectively, Sigma) for the duration of the experi-
ment. T cell proliferation was assessed at days 2 and 4
post-infection by CellTrace™ CFSE Cell Proliferation Kit
(Molecular Probes, Eugene, OR) and FACS analyses
together with reverse transcriptase activity [16].
Clinical Investigations
The Southern Alberta Clinic (SAC) is a multidisciplinary,
geographically-based clinical program, which provides
care to all HIV seropositive patients in southern Alberta,
Canada [17]. Participation in this study was voluntary
and an informed consent was approved by the University
of Calgary Ethics Committee. Clinical and laboratory
variables were assessed every three to four months, which
included complete blood counts, electrolytes, hepatic and
renal function tests, blood CD4+/CD8+ T cell levels,
plasma viral loads and serum AED levels, when indicated.
The principal objective at SAC of cART treatment is to
suppress virus in blood to undetectable levels (≤1.6 log10
copies/ml). SAC has access to all contemporary antiretro-
viral drugs approved in Canada.
All adult patients receiving AEDs were identified within
the clinic database (Jan 01/2001-May 01/2007), an in-
house computerized database containing all relevant
patient characteristics dating back to 1985, which is
updated with each patient visit to the clinic. Clinical
aspects, laboratory findings, demographic features and
AED usage were analyzed. Liver function tests (LFTs)
(alkaline phosphatase, alanine aminotransferase (ALT),
aspartate aminotransferase (AST), total bilirubin) were
recorded for every AED-treated patient during AED ther-
apy. The severity of hepatotoxicity was graded based on
the guideline of AIDS clinical trial group (ACTG) [18]
and the total number of abnormal LFTs was recorded.
Cumulative AED dosing was calculated for all patients;
cumulative dose (g) was the summation of the days that
patients received AEDs multiplied by the dose and fre-
quency to the date of AED being stopped or to the end of
the follow up period (May 01/2008).
AED-treated patients were stratified into two groups
based on virologic status: AED-receiving patients were
defined as "aviremic" if they had been receiving cART for
a t  l e a s t  o n e  m o n t h  w i t h  a n  u n d e t e c t a b l e  p l a s m a  v i r a l
(aviremic) load (≤ 1.6 log10 copies/ml) prior to the intro-
duction of an AED and remained on the same cART regi-
men for the full duration of AED exposure/therapy and
had no episodic of protracted virologic failure (>2 log10
copies/ml) during the period of concomitant exposure to
cART and AED; patients were defined as "viremic" if they
had detectable viral loads, because they were unable to
maintain sustained adherence to drug therapies or had
not received antiretroviral therapy prior to AED treat-
ment. The viral load, CD4+ and CD8+ T cell levels prior
to initiating AED therapy (baseline) were compared with
corresponding values at 6 and 12 month follow-up visits.
Patients were not included in this sub-analysis if they did
not have viral loads or CD4+ T cell levels prior to the ini-
tiation of AED therapy or received AED therapy less than
6 months.
Statistical analysis
In vitro data were tested by one-way ANOVA with post-
hoc  Tukey-Kramer. Demographic and clinical variables
were analyzed by the Kruskal-Wallis and Chi-square tests
for non-parametric continuous and categorical variables,
respectively. The levels of CD4+ and CD8+ T cells were
tested by Friedman test for non-parametric repeated
measures ANOVA with Dunn's multiple comparisons
test as a post hoc analysis. The level of significance was
defined as p less than 0.05 for all tests.Lee et al. BMC Neurology 2010, 10:44
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Results
Cell culture studies
Previous studies have reported that exposure to different
AEDs influenced both HIV replication and leukocyte via-
bility or proliferation [14,19-22]. To investigate the com-
parative effects of commonly used AEDs, human primary
blood lymphocytes (PBLs) with and without concurrent
HIV-1 infection were treated with gabapentin, valproate
or phenytoin at therapeutic concentrations. These studies
revealed that HIV infection suppressed T cell prolifera-
tion  in vitro (Figure 1B and 1C) compared with unin-
fected (Figure 1A and 1C) cell cultures at day 2 post-
infection in cells, as expected. However, valproate expo-
sure to PBLs suppressed T cell proliferation in both HIV-
infected and uninfected cultures in comparison with
untreated cultures (Figure 1C). Conversely, gabapentin
and phenytoin did not influence T cell proliferation in
vitro  (Figure 1C). None of the present AEDs exerted
effects on viral production in terms of reverse tran-
scriptase activity in supernatants from PBLs relative to
untreated HIV-infected cultures (Figure 1D). A sub-anal-
ysis of valproate exposure on T cell proliferation at day 3
post infection showed that valproate not only reduced
but also altered proliferation pattern (Figure 2A-C). In
uninfected lymphocyte cultures, the valproate-treated
cells displayed higher parent generation (P) and genera-
tion 1 (G1) and lower generation 3 (G3) levels than the
untreated group. The majority of cells in HIV-infected
PBLs with valproate exposure remained undivided (P
generation) while HIV-infected PBLs divided two times
in the absence of valproate (Figure 2B and 2D). Similar
effects were observed at day 4 post-infections (data not
shown). These studies highlighted the potential impact of
valproate on T cell function while also indicating a rela-
tive lack of effect on viral replication mediated by any of
the AEDs on proliferating T cells, prompting us to anal-
yse the clinical effects of these same AEDs.
Demographic and clinical features of AED-exposed persons
169 persons (12.6%) were exposed to AED therapy among
all HIV/AIDS patients (n = 1345) actively receiving care
at SAC during the study period in the current cohort.
Comparison of demographic and clinical features of
AED-treated viremic and aviremic (stable cART regimen)
patients disclosed no differences in age, mortality, AIDS
status, gender, ethnicity, HIV risk factor, duration of HIV
infection and CD4+ T cell nadir and viral burden at the
time of first diagnosis although CD4+ T cell levels were
significantly higher at the time of HIV diagnosis in the
viremic group (Table 1). Collectively, these findings
implied that these two groups shared similar clinical fea-
tures.
AED indication, type and cumulative exposure
The indications for AED therapy in the present cohort of
patients were identified as peripheral neuropathy/neuro-
pathic pain, seizure/epilepsy, mood disorders, movement
disorders and other (headache) (Figure 3A). The AEDs
that were prescribed in the included gabapentin/pregaba-
lin, valproate, carbamazepine, lamotrigine, phenytoin,
topiramate and others (phenobarbital, levetiracetam and
primidone) (Figure 3B). Gabapentin was the most fre-
quently prescribed AED in patients who were viremic or
aviremic. The use of other AEDs except phenytoin was
also similar in both groups. Multiple AEDs were pre-
scribed in a subset of patients including 2 AEDs (13.3%)
and 3 or more AEDs (9.0%). There were 143 of 169
patients who were cART-experienced with median cART
exposure time of 75 months (IQR 33.3-116.5). As some
patients required AED therapy for lengthy periods, we
analysed the median cumulative exposures of the major
AEDs during the study period. Among all AED-treated
patients, the median total AED cumulative lifetime expo-
sures (g) were: gabapentin, 699; valproate, 574; carbam-
azepine, 282; lamotrigine, 18; phenytoin, 195; and
topiramate, 41. Aviremic patients showed a lower median
total AED cumulative lifetime doses of carbamazepine,
lamotrigine and phenytoin than viremic patients (Figure
3C). These findings underscored the variation in dosing
for different AEDs while also highlighting the substantial
exposure to AED therapies within the present cohort.
Liver function tests and AED toxicity
The potential for metabolic interactions between AEDs
and different cART regimens is substantial, particularly
in terms of ensuing hepatic dysfunction [23]. To address
this issue, the frequency and severity of abnormal labora-
tory tests was investigated among viremic patients as well
as those who were aviremic. Both groups showed a simi-
lar profile of abnormalities in liver function tests (LFTs)
with no abnormalities in half of patients and one abnor-
mal LFT in one-third of patients (Figure 3D). Of the
patients who had ≥3 or more LFT abnormalities 8 out of
9 patients received gabapentin. In addition, 54% of
patients with gabapentin use experienced at least one
abnormal LFT during AED therapy (Figure 3E). Interest-
ingly, aviremic patients with concurrent use of valproate
and stable cART regimens experienced a 3 fold higher
risk of LFT abnormalities (Figure 3D). The most frequent
abnormal LFT was elevated ALT (36.7%), followed by ele-
vated alkaline phosphatase (16.9%), hyperbilirubinemia
(9.6%) and elevated AST (9.0%). Most of abnormal LFTs
were mild and were categorized as grade 1 hepatotoxicity
in both groups except hyperbilirubinemia (Figure 3E and
Additional file 1 Figure S1A-C). Only one-third of
patients in both groups were experienced one additional
LFT abnormality and approximately 10% of patients dis-
played two or more additional LFT abnormalities (Addi-
tional file 1 Figure S1D). Of overall importance, no events
of overt hepatic or virologic failure were identified within
these AED-treated patient groups regardless of clinicalLee et al. BMC Neurology 2010, 10:44
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Figure 1 In vitro effects of AEDs on T cell proliferation and viral replication. (A) and (B) FACS analysis of cultured CD3+ T cells following mock 
(HIV (-)) and HIV (HIV (+)) infection in the (i) absence or (ii) presence of valproate treatment (75 μg/ml) showing reduced proliferation in valproate-
treated cultures at day 2 post-infection. (C) Valproate exerted a suppressive effect on T cell proliferation with and without HIV infection in contrast to 
the other AEDs. (D) None of the AEDs affected HIV replication in CD3+ T cells, measured as reverse transcriptase activity in culture supernatants col-
lected at day 2 and 4 post-infection. Data represent mean ± SEM. (Tukey-Kramer post hoc test, **p < 0.01)
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Figure 2 In vitro effects of Valproate on T cell proliferation and viral replication at day 3 post-infection. (A) and (B) FACS analysis of cultured 
CD3+ T cells following mock (HIV (-)) and HIV (HIV(+)) infection in the (i) absence or (ii) presence of valproate treatment (75 μg/ml) showing reduced 
proliferation in valproate-treated cultures at day 3 post-infection. In the absence of valproate, most T cells divided one to three times while in the pres-
ence of valproate, the majority of T cells remained in a parent generation (P). (C) Exposure to valproate also reduced T cell proliferation with and with-
out HIV infection at day 3 post-infection. (D) Exposure to valproate skewed the proliferation pattern of uninfected (HIV(-)) and HIV-infected (HIV(+)) 
PBLs. There were more parent generation (P) and less generation 3 (G3) lymphocytes in valproate-treated groups. Data represent mean ± SEM. (Tukey-
Kramer post hoc test, **p < 0.01)
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grouping during the study period. Similarly, other organ
failures, hospitalization or death due to AED-mediated
adverse effects were not observed in this cohort.
Impact of AED therapy on infection status
Previous studies suggest that AEDs might exert differen-
tial effects on viral replication and perhaps also affect
lymphocyte activation state or phenotype [14,24]. To
assess these effects in vivo, AEDs were classified based on
their putative mechanisms of action within the cART and
AED-exposed aviremic group including calcium channel
blockers (CCB: gabapentin/pregabalin) (55.4%), sodium
channel blockers (SCB: phenytoin, carbamazepine, lam-
otrigine) (21.5%), valproate (13.9%), and Others (topira-
mate, levetiracetam) (9.2%). Among the 55 patients in
this group, 8 were treated with more than one AED at dif-
ferent times during the study period. Viremic patients or
ARV-naïve patients had detectable viral loads (>2 log10
copies/ml) (Figure 4A). Mean plasma viral (log10) loads
were maintained at or near detection levels in aviremic
group during the 12 months of treatment irrespective of
whatever AED prescribed to the patients (Figure 4B).
Aviremic patients receiving CCBs, SCBs or valproate
showed similar demographic profiles and there was no
difference between the baseline CD4+ T cell level (0
month) (Figure 4D). Over the 12 month follow-up period
beginning at the initiation of AED therapy, mean blood
CD4+ T cell levels in viremic patients did not change in
AED treatment group (Figure 4C). In contrast, mean
blood CD4+ T cell levels at 6 and 12 follow-up months
increased significantly among aviremic patients treated
with SCBs or CCBs but not in patients treated with val-
proate (Figure 4D). Mean blood CD8+ T cell levels
remained unchanged during the 12 follow-up months in
both patient groups with all AED therapies (Figure 4E-F).
These findings implied that AED exposure had little
effect on plasma viral load levels and blood CD8+ T cell
levels but there was a contemporaneous increase in blood
CD4+ T cell levels in aviremic patients treated with cART
and calcium or sodium channel blocking agents.
Discussion
The present study provides the first longitudinal analysis
of cumulative AED use in patients with serious systemic
Table 1: Demographic and clinical characteristics of HIV/AIDS patients with antiepileptic drug (AED) exposure.
Viremic Aviremic p value
N 114 55
Median age (IQ range) 46.2 (40.0-52.0) 49.2 (42.1-56.2) NS
Median age at HIV diagnosis (IQ range) 33.8 (27.0-41.95) 36.0 (27.4-44.9) NS
Male gender 84 (73.7%) 44 (80.0%) NS
Ethnicity NS
Caucasian 90 (78.9%) 43 (78.2%)
Aboriginal/Inuit/Metis 7 (6.1%) 3 (5.5%)
Black 7 (6.1%) 3 (5.5%)
Others 10 (8.9%) 6 (10.9%)
HIV risk factor NS
Homosexual/Bisexual 51 (44.7%) 26 (47.3%)
IVDU 36 (31.6%) 13 (23.6%)
Others 27 (23.7%) 16 (29.1%)
HCV 39 (34.2%) 12 (21.8%) NS
Median duration of HIV infection (years) (IQ range) 11.7 (7.5-16.6) 12.6 (8.9-16.7) NS
Median baseline CD4+ T cell (cells/mm3) (IQ range) 371 (185-583) 241 (104-457) <0.05
Median nadir CD4+ T cell (cells/mm3) (IQ range) 120 (26-196) 125 (32-222) NS
Median baseline CD8+ T cell (cells/mm3) (IQ range) 784 (557-1134) 726 (515-1120) NS
Median baseline log10 viral load (copies/ml) (IQ range) 4.5 (3.5-5.1) 4.3 (3.3-5.0) NS
Late presenter (%) 34 (29.8%) 22 (40.0%) NS
AIDS-defining illness 50 (43.9%) 24 (43.6%) NS
Mortality (%) 23 (20.2%) 8 (14.5%) NS
IQ range: Interquartile rangeLee et al. BMC Neurology 2010, 10:44
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Figure 3 Indication, frequency, cumulative exposure and liver toxicity of AEDs. (A) Neuropathic pain represented the most common indication 
for AED treatment although seizures/epilepsy, mood and movement disorders were other reasons for prescribing AEDs. (B) A similar profile of AED 
prescription was observed in viremic (open box) or aviremic (filled box) patients. Gabapentin was the most frequently prescribed AED. The use of phe-
nytoin was significantly lower in patients with stable ART regimens. (Chi-square test, *p < 0.05). (C) Cumulative AED dosing for patients receiving AEDs 
disclosed that gabapentin and valproate showed the highest levels of cumulative drug exposures. Among aviremic patients, the profile of cumulative 
dosing was similar to patients with detectable viral loads. (D) The frequency of abnormal liver function tests (LFTs) in aviremic patients with concurrent 
use of AED did not differ from AED-treated viremic persons. (E) The risks of abnormal LFTs in patients receiving gabapentin, carbamazepine, lamotrig-
ine and topiramate were similar in viremic or aviremic patients while the risk of abnormal LFTs were three-times higher in aviremic patients receiving 
valproate. (F) Severity of hepatotoxicity was categorized based on AIDS clinical trial group (ACTG) guidelines. AED-treated viremic or aviremic patients 
displayed a similar profile of hepatotoxicity in the levels of alanine aminotransferase (ALT). (N.D.: non detectable)
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Figure 4 AEDs and their effects on immune parameters. (A) In viremic or ART-naïve patients, mean log10 viral load in patients treated with sodium 
channel blockers (SCB: carbamazepine, lamotrigine and phenytoin; N = 44), calcium channel blockers (CCB: gabapentin, pregabalin; N = 65) and val-
proate (N = 20) were higher than the detection limit at all time points. (B) In all AED-treated aviremic patients, mean log10 viral loads were maintained 
at or near detection levels throughout the 12 month follow-up period. (C) Mean blood CD4+ T cell levels were constant over the 12 months in viremic 
patients. (D) In contrast, aviremic patients receiving SCB (N = 14) and CCB (N = 36) cART had higher CD4+ T cell levels at 6 and 12 months compared 
to the baseline while there was no change in CD4+ T cell levels in patients treated with valproate. (E and F) AED therapies did not affect blood CD8+ 
T cell levels in both patient groups. (Friedman test with Dunn's multiple comparison post hoc test; *p < 0.05)
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comorbidities and at high risk of drug interactions.
Indeed, AEDs were prescribed for multiple indications
with limited side-effects in this broadly representative
regional population of HIV-infected persons. Despite fre-
quent use and high cumulative doses of AEDs, no events
of virologic or organ failure, attributable to AED use were
recorded. Drugs within all of the AED classes were pre-
scribed herein but sodium and calcium channel blocking
AEDs were the most commonly observed with associated
benefits in terms of a rise in CD4+ T cell levels over time
while valproate was not associated with improvement in
systemic immunity. The frequent use (>10%) of AEDs in
HIV/AIDS patients also underscored the burden of neu-
ropsychiatric diseases within this patient population yet
provides assurance that AEDs can be used safely among
patients receiving cART without serious adverse conse-
quences.
Due to the numerous potential interactions between
AEDs and cART in terms of hepatic metabolism, neurop-
sychiatric and renal side-effects, the relative paucity of
adverse events herein was encouraging. In fact, minimal
changes in AEDs regimens were required, as dictated by
measured AED blood levels. In some instances, the AED
dosages were increased to compensate for increased
metabolism to achieve therapeutic AED blood levels.
Although 1/3 of patients exhibited one abnormal LFT, the
severities of abnormal LFTs were mild. This relative lack
of undesirable interactions might have been due to regu-
l a r  c l i n i c a l  m o n i t o r i n g  o f  p a t i e n t s  w i t h  r e p e a t e d  A E D
blood levels when available (valproate, carbamazepine,
phenytoin) together with the frequent use of gabapentin/
pregabalin, which are excreted renally. Importantly, pre-
vious studies suggest that AEDs including gabapentin and
lamotrigine were well tolerated when prescribed to
patients with HIV/AIDS [11,25,26]. Nonetheless, the risk
o f  a b n o rm a l  LFT s  i s  c o n s i d e r a b l e  wi t h i n  t h is  gr o u p  o f
patients; several explanations for these abnormalities lie
in the demographics of the cohort including the compar-
atively high risk of hepatitis virus infection, substance
abuse and other concomitant medical issues accompany-
ing immune suppression.
In the present study, several patients were receiving val-
proate; of interest, earlier studies suggested that valproate
increased HIV replication in vitro although the mecha-
nism remains uncertain but this effect was thought to
enhance clinical clearance of the virus from tissue reser-
voirs, eventually improving clinical outcomes [24]. How-
ever, the present experimental studies indicated that
valproate, phenytoin and gabapentin had no effects on
viral replication on T cells infected with a CCR5-depen-
dent strain of HIV-1, similar to a previous study [14].
Conversely, valproate suppressed T cell proliferation in
vitro regardless of the presence or absence of concomi-
tant HIV infection, suggesting that valproate influenced
the ability of T cells to divide efficiently and further anal-
ysis on the effects of antiepileptic drugs on T cell subpop-
ulation is of interest. Indeed, valproate has recently been
shown to affect proliferation of malignant cells [27,28]
but had no in vivo effects on viral replication or CD4+ T
cell levels [22,29-31]. However, the current studies
showed that concurrent use of calcium (gabapentin,
pregabalin) and sodium (carbamazepine, phenytoin, lam-
otrigine) channel blocking drugs with stable cART regi-
mens, which maintained aviremia, exerted a benefit in
terms of increased median CD4+ T cell levels in blood
over a 12 month period. Several potential explanations
underlie this observation including blocking cation chan-
nels and thus stabilizing lymphocyte membrane poten-
tials and/or suppressing intracellular death signalling
pathways, thereby, preventing leukocyte depletion. Alter-
natively, the rise in CD4+ T cell levels might reflect
greater patient adherence to cART regimens because they
are experiencing a better quality of life due to AED usage.
Whatever the explanation for this finding, it warrants
further investigation because it might provide insight into
additive benefits for the treatment of HIV/AIDS.
Conclusion
This report is the first to assess cumulative exposure of
multiple AEDs in any population over time. Despite high
cumulative doses of different AEDs, our study showed
that the use of several AEDs in HIV-infected patients
receiving cART was comparatively safe and might be ben-
eficial to immune status. These findings are clinically rel-
evant because AEDs are widely prescribed in HIV-
infected patients with various neuropsychiatric syn-
dromes, as well as in the general population. In summary,
this is the first analysis of AED use and effects in HIV/
AIDS patients closely monitored in a clinical setting, but
also raised interesting questions to be explored in the
future regarding immune benefits of AEDs and their
underlying mechanisms.
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